These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7489619)

  • 1. Cell death in the failing heart: role of an unnatural growth response to overload.
    Katz AM
    Clin Cardiol; 1995 Sep; 18(9 Suppl 4):IV36-44. PubMed ID: 7489619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maladaptive growth in the failing heart: the cardiomyopathy of overload.
    Katz AM
    Cardiovasc Drugs Ther; 2002 May; 16(3):245-9. PubMed ID: 12374903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiomyopathy of overload: an unnatural growth response.
    Katz AM
    Eur Heart J; 1995 Dec; 16 Suppl O():110-4. PubMed ID: 8682075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardiomyopathy of overload: a hypothesis.
    Katz AM
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S68-71. PubMed ID: 1725047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart.
    Katz AM
    Ann Intern Med; 1994 Sep; 121(5):363-71. PubMed ID: 8042826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart.
    Katz AM
    Trends Cardiovasc Med; 1995; 5(1):37-44. PubMed ID: 21232236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
    Hamada M; Hara Y; Ohtsuka T; Suzuki J; Saeki H; Ogimoto A; Shigematsu Y
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S5-10. PubMed ID: 12688389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy for heart failure].
    Just H
    Ther Umsch; 2000 May; 57(5):313-20. PubMed ID: 10859991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis of hypertrophic and dilated cardiomyopathy].
    Ikeda H; Imaizumi T
    Nihon Rinsho; 2000 Jan; 58(1):86-92. PubMed ID: 10885294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Refractory heart failure: it requires the use of polychemotherapy. What is the rationale?].
    Campa PP; Puddu PE; Schiariti M; Monti F; Dawodu AA; Gentile C; Lilla Della Monica PL; Vaccaro M; De Biase L
    Cardiologia; 1995 Dec; 40(12 Suppl 1):139-50. PubMed ID: 8998706
    [No Abstract]   [Full Text] [Related]  

  • 11. Carvedilol in heart failure.
    Kelly DT
    Cardiology; 1993; 82 Suppl 3():45-9. PubMed ID: 8106165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How and to what extent has beta-blocker treatment been established for chronic heart failure?].
    Yokota Y
    J Cardiol; 1996 Aug; 28(2):99-112. PubMed ID: 8814528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy.
    Hoshikawa E; Matsumura Y; Kubo T; Okawa M; Yamasaki N; Kitaoka H; Furuno T; Takata J; Doi YL
    Am J Cardiol; 2011 Apr; 107(7):1065-70. PubMed ID: 21296328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic alternatives in dilated cardiomyopathy--a review of current options.
    Kleber FX
    Eur Heart J; 1991 Aug; 12 Suppl D():197-9. PubMed ID: 1680688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are Angiotensin-converting enzyme inhibitors and beta-blockers ineffective in children with dilated cardiomyopathy and heart failure?
    Singh TP; Almond C
    J Am Coll Cardiol; 2010 Aug; 56(10):823; author reply 823-4. PubMed ID: 20797500
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.
    Castelli G; Fornaro A; Ciaccheri M; Dolara A; Troiani V; Tomberli B; Olivotto I; Gensini GF
    Circ Heart Fail; 2013 Sep; 6(5):913-21. PubMed ID: 23888044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
    Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
    Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heart failure due to dilated cardiomyopathy].
    Hiramitsu S; Miyagishima K; Mori K; Kimura H
    Nihon Rinsho; 2007 May; 65 Suppl 5():421-4. PubMed ID: 17569321
    [No Abstract]   [Full Text] [Related]  

  • 19. Placental growth factor regulates cardiac inflammation through the tissue inhibitor of metalloproteinases-3/tumor necrosis factor-α-converting enzyme axis: crucial role for adaptive cardiac remodeling during cardiac pressure overload.
    Carnevale D; Cifelli G; Mascio G; Madonna M; Sbroggiò M; Perrino C; Persico MG; Frati G; Lembo G
    Circulation; 2011 Sep; 124(12):1337-50. PubMed ID: 21900081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
    Tatli E; Kurum T
    Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.